Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Oilminerdeluxeon Jan 08, 2022 1:04am
244 Views
Post# 34295672

RE:RE:RE:RE:RE:RE:Level ll Quote

RE:RE:RE:RE:RE:RE:Level ll QuoteIf they intend to tell us if they have applied for, or will, that BTD, next week is a good time for that. If so, I suspect that a few more patients have been checked with CR. If it drags on, well maybe they weren't CR. But who knows. Just speculating.  Maybe they will not even tell us when they apply. Anyway, the next update should have a lot of data in it. 6 months for a bunch of people and half a dozen or so fresh ones at 3 months. Hopefully, old tricks of dropping to the twenties will not be happening in the mean time. 

When a GBM phase 1 trial starts, how many people would be ideal? A very small trial or as many patients as possible? The costs will of course increase the more people who are in it but if they have the goods in the end, that should not matter much one would think.

Let's break 40 cents in Q1!
<< Previous
Bullboard Posts
Next >>